Pharma CEO Pair Become China’s Richest Couple
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Address: Institute of Medicinal Plant Development
151 Ma Lian Wa North Road, Haidian District
Beijing, P.R.China, 100193,China
Tel: +86 10 62899958
Web: www.abo.org.cn
ALLIANCE OF BIO-BOX OUTSOURCING, CHINA (ABO) is a member-based organization, devoted to excellence in providing high quality, efficient and cost-effective services and promoting international collaborations between China and the world.
ABO was founded in 2005 by the Beijing Pharma and Biotech Center (BPBC), together with 10 leading biotech outsourcing providers in China.
ABO provides a broad range of services, from drug discovery, pre-clinical studies, clinical trials, to registration and contract manufacturing. Alliance of Bio-Box Outsourcing China offers hassle-free outsourcing experiences with global quality standards.
Genomics Studies & Proteomics Studies, Genetic Engineering & Protein Engineering, Genetic Therapeutics, Antibody Engineering, Drug Screening Pharmacokinetics & Drug Safety Evaluation, Pilot Plan Trials, Clinical Trials, Contract Manufacturing
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to…
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in…
More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that continuously surpasses that of the US and other developed…
Hong Kong is now the world’s second largest funding hub for biotech according to Hong Kong Chief Executive Carrie Lam. During her speech at the 2nd HKEx Biotech Summit on…
On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of Shanghai, China. Following a global re-organization mid-2018, Pfizer now operates three business…
Carsten Lu of Chinese biotech Adlai Nortye outlines his strategy for navigating a crowded immuno-oncology field in China, his partnership strategy, and the firm’s early move to establish a footprint…
Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps…
See our Cookie Privacy Policy Here
